U.S. Markets open in 5 hrs 32 mins

Grifols, S.A. (GRFS)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
20.28-0.21 (-1.02%)
At close: 4:00PM EDT
People also watch
IRWDSHPGAKRXCBPOEPZM

Grifols, S.A.

Avinguda de la Generalitat
152-158Parc de Negocis Can Sant Joan
Barcelona 08174
Spain
34 93 571 05 00
http://www.grifols.com

Sector
Industry
Full Time Employees16,808

Key Executives

NameTitlePayExercisedAge
Mr. Raimon Grifols RouraCo-Chief Exec. Officer and Exec. DirectorN/AN/A53
Mr. Ramón Riera RocaExec. VP, Pres of Global Commercial Division and Exec. Director1.08MN/A62
Mr. Tomás Dagá GelabertVice Sec. and External DirectorN/AN/A61
Mr. Víctor Grifols DeuCo-Chief Exec. Officer and Exec. DirectorN/AN/A40
Mr. Alfredo Arroyo GuerraChief Financial Officer and Corp. VPN/AN/A59
Amounts are as of December 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Grifols, S.A., a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics. It operates through four segments: Bioscience, Diagnostic, Hospital, and Raw Materials and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use, including the reception, analysis, quarantine, classification, fractionation, and purification of plasma; and sells and distributes end products. This segment offers plasma products, such as IVIG, Factor VIII, A1PI, and albumin; and intramuscular immunoglobulins, ATIII, Factor IX, and plasma thromboplastin components. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products comprising analytical instruments, reagents, software, and related products for use in clinical and blood bank laboratories. This segment serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital segment manufactures and installs products used by hospitals consisting of parenteral solutions, and enteral and parenteral nutritional fluids. The Raw Materials and Others segment sells intermediate biological products; and renders manufacturing services to third party companies. The company also offers engineering services. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves hospitals and clinics, group purchasing organizations, governments, and other distributors through sales representatives, marketing partners, and third-party distributors. Grifols, S.A. was founded in 1940 and is headquartered in Barcelona, Spain.

Corporate Governance

Grifols, S.A.’s ISS Governance QualityScore as of August 1, 2017 is 3. The pillar scores are Audit: 1; Board: 2; Shareholder Rights: 6; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.